DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Reducing Reconsolidation of Trauma Memories With Propranolol

Information source: Douglas Mental Health University Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Posttraumatic Stress Disorder

Intervention: Propranolol (Drug); Short acting + long acting propranolol + memory reactivation (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Douglas Mental Health University Institute

Official(s) and/or principal investigator(s):
Alain Brunet, Ph.D., Principal Investigator, Affiliation: Douglas Institute Research Centre

Overall contact:
Alain R Brunet, Ph.D., Phone: 514-761-6131, Ext: 4348, Email: alain.brunet@mcgill.ca


The purpose of this study is to test whether propranolol is capable of reducing subsequent physiological trauma-related conditioned responses, as well as self-reported post-traumatic stress disorder (PTSD) symptoms.

Clinical Details

Official title: Reduction of the Reconsolidation of the Trauma Memory With Propranolol

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:


Heart rate

Skin conductance

Secondary outcome:

PTSD symptom levels

Quality of life

Memory Experience

Psychophysiological assessments


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Suffer from chronic PTSD for at least 6 consecutive months;

- Obtain a score of 33 or more on the Impact of Events Scale-Revised:

- For participants aged 40 years: accept to undergo an electrocardiogram assessment.

The results of the electrocardiogram must be normal;

- Accept to not commence taking new medications on a regular basis during the study.

Exclusion Criteria:

- Hypotension;

- Cardiac rhythm below 55 beats per minute;

- Medical conditions that contraindicates the administration of propranolol;

- Previous adverse reaction to, or non-compliance with, beta-blockers;

- Current use of medication that may involve potentially dangerous interactions with


- Any medication that can have an impact on cardiac rhythm;

- Women who are breast feeding;

- Past or present bipolar disorder or psychosis,

- Present substance abuse or dependence, suicidal ideation;

- Participating in psychotherapy other than support psychotherapy;

- An average score above 20 on the Dissociative Experience Scale.

Locations and Contacts

Alain R Brunet, Ph.D., Phone: 514-761-6131, Ext: 4348, Email: alain.brunet@mcgill.ca

Douglas Mental Health University Institute, Verdun, Quebec H4H 1R3, Canada; Recruiting
Andrea Ashbaugh, Ph.D., Phone: 514-761-6131, Ext: 4341, Email: andrea.ashbaugh@douglas.mcgill.ca
Alain Brunet, Ph.D., Principal Investigator
Additional Information

PTSD research website

Related publications:

Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK. Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2008 May;42(6):503-6. Epub 2007 Jun 22.

Starting date: March 2011
Last updated: June 23, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017